About TNMS
Therapeutic Neuromodulation Systems (TNMS) offers drug-free treatments for pain management, recovery after surgery and opioid withdrawal. Its Morph Device is a nerve field stimulator that works through the skin and is prescribed by a physician. The Morph Device is a Class II medical device, and TNMS also makes POSP and MD devices.
The company is based in Metairie, Louisiana, and works with physicians through a provider program. Arnold Rougee is its manager.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 15, 2017 | Sep 21, 2026 | $1,709,500of $5.0M target | 29 | $58,948 | EquityRule 506(b) | Form D ↗ |
| Oct 15, 2017 | Sep 11, 2026 | $969,500of $5.0M target | 33 | $29,379 | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $2,679,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed TNMS
Investors backed TNMS for small nerve stimulation devices that treat pain and opioid withdrawal without drugs. A physician prescribes the device, which stimulates nerve fields through the skin. TNMS pitches it as a safer, faster and simpler way to manage withdrawal symptoms.
The problem it targets
TNMS's case is that its devices are a safer, faster, and simpler solution for managing opioid withdrawal symptoms. It also offers them for pain management and recovery after surgery.
What the product does
The Morph Device is a percutaneous nerve field stimulator: a physician-prescribed device that delivers electrical stimulation to nerve fields near the skin. The site lists it as a Class II medical device and offers two more devices, called POSP and MD. Physicians reach the company through a provider program with its own login.
We wrote this summary from public statements by TNMS and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on TNMS's Form D filed Sep 21, 2026.